Selective granulocyte and monocyte apheresis as a new adjunct to enhance the efficacy of interferon-alpha + ribavirin in patients with high plasma hepatitis C virus

Digestive and Liver Disease

Volumn 37, Issue 7, 2005, Pages 515-521

  Sawada, K ^a   Kashiwamura, S ^b   Okamura, H ^b   Ohnishi, K ^c   Fukunaga, K ^c   Hirata, I ^d   Saniabadi, A ^d  

^a Fujimoto Hospital Medicine   (Japan)

^b Institution for Advanced Medical Sciences   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d Japan Immunoresearch Institute   (Japan)

Author keywords

Active complement; Granulocytes and monocytes apheresis; Hepatitis C virus; Interferon alpha

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; COMPLEMENT; OPSONIN; RIBAVIRIN; VIRUS RNA; ALPHA2B INTERFERON; IMMUNOLOGICAL ADJUVANT;

ADSORPTION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; APHERESIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; FEMALE; GENOTYPE; GRANULOCYTE; HAIR LOSS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOCYTE; MACROPHAGE; MALE; MONOCYTE; PATIENT COMPLIANCE; PATIENT SAFETY; REMISSION; RNA ANALYSIS; BLOOD; DRUG COMBINATION; IMMUNOLOGY; LEUKAPHERESIS; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ALANINE TRANSAMINASE; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LEUKAPHERESIS; MALE; MIDDLE AGED; MONOCYTES; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 26944433491     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.01.014     Document Type: Article

References (36)

1. Kobayashi M., Tanaka E., Sodeyama T., Urushihara A., Matsumoto A., and Kiyosawa K. The natural course of hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C virus. Hepatology 23 (1996) 695-699
2. Arase Y., Ikeda K., Chayama K., Murashima N., Tsubota A., Suzuki Y., et al. Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course. J Gastroenterol 35 (2000) 607-612
3. Kiyosawa K., Tanaka E., and Sodeyama T. Hepatitis C virus and hepatocellular carcinoma. In: Reesink H.W. (Ed). Hepatitis C virus. Curr. Srud. Hematol. Trans. vol. 62 (1998), Karger, Basel 161-180
4. Cravatto M., Pozzato G., Zorat F., Pusini E., and Sentini G. Peripheral blood neutrophils from hepatitis C virus-infected patients are replication sites for the virus. Haematologica 85 (2000) 356-361
5. Caussin-Scwemling C., Scmitt C., and Stoll-Keller F. Study of the infection of human blood derived monocyte/macrophage with hepatitis C virus in vitro. J Med Virol 65 (2001) 14-22
6. Bouffard P., Hayashi P.H., Acevedo R., Levy N., and Zeldis J.B. Hepatitis C is detected in a monocyte macrophage subpopulation of peripheral blood mononuclear cells of infected patients. J Infect Dis 166 (1992) 1276-1280
7. Shimoyama T., Sawada K., Hiwatashi N., Sawada T., Matsueda K., Munakata A., et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 16 (2001) 1-9
8. Saniabadi A.R., Hanai H., Takeuchi K., Bjarnason I., and Lofberg R. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 7 (2003) 48-59
9. Sawada K., Muto T., Shimoyama T., Satomi M., Sawada T., Nagawa H., et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 9 (2003) 307-321
10. D'Arrigo C., Candal-Couto J.J., Greer M., Veale D.J., and Woof J.M. Human neutrophil Fc receptor-mediated adhesion under flow: a hallow fiber model of intravascular arrest. Clin Exp Immunol 100 (1993) 173-179
11. Hiraishi K., Takeda Y., Shiobara N., and Saniabadi A. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 7 (2003) 334-340
12. Ohara M., Saniabadi A.R., Hirata I., and Kasukawa R. Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 21 (1997) 989-994
13. Lau J., Davis G., and Kniffen J. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 342 (1993) 1502-1504
14. Kanke K., Nakano M., Hiraishi H., and Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 36 (2004) 811-817
15. Di Bisceglie A.M., Martin P., Kassianides C., and Lisker-Melman M. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double blind placebo-controlled trial. N Engl J Med 321 (1989) 1506-1510
16. Tsubota A., Chayama K., and Ikeda K. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 19 (1994) 1088-1094
17. Sawada K., Ohnishi K., Fukunaga K., and Shimoyama T. A new treatment for HCV-ulcerative colitis co-morbidity intolerant to IFN-alpha. Am J Gastroenterol 98 (2003) 228-289
18. Hanai H., Watanabe F., Takeuchi K., Saniabadi A., and Bjarnason I. Leucocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin Gastroenterol Hepatol 1 (2003) 28-35
19. Kashiwagi N., Saniabadi A., and Shimoyama T. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 47 (2002) 1334-1341
20. Suzuki Y., Yoshimura N., Saniabadi A.R., and Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 49 (2004) 565-571
21. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 (2003) 659-662
22. Chang K.M. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 7 (2003) 89-105
23. Sreenarasimhaiah J., Jaramillo A., Crippin J., Lisker-Melman M., Chapman W.C., and Mohanakumar T. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection. Hum Immunol 64 (2003) 497-504
24. Shinohara M., Ishii K., and Takamura N. Long-term changes of peripheral blood CD4-positive T cell subsets (Th1, Th2) in chronic hepatitis C patients with a sustained response or no response to IFN. Hepatol Res 27 (2003) 260-265
25. Kashiwagi N., Hirata I., and Kasukawa R. A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher 2 (1998) 134-141
26. Hanai H., Watanabe F., Saniabadi A., Matsushita I., Takeuchi K., and Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 47 (2002) 2349-2353
27. Ilangumaran S., and Rottapel R. Regulation of cytokine receptor signaling by SOCS1. Immunol Rev 192 (2003) 196-211
28. Cornish A.L., Chong M.M., Davey G.M., Darwiche R., Nicola N.A., Hilton D.J., et al. Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other gamma c-dependent cytokines in peripheral T cells. J Biol Chem 278 (2003) 22755-22761
29. Yu C.R., Mahdi R.M., Ebong S., Vistica B.P., Gery I., and Egwuagu C.E. Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells. J Biol Chem 278 (2003) 29752-29759
30. Song M.M., and Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 273 (1998) 35056-35062
31. Brysha M., Zhang J.G., Bertolino P., Corbin J.E., Alexander W.S., Nicola N.A., et al. Suppressor of cytokine signaling-1 attenuates the duration of interferon gamma signal transduction in vitro and in vivo. J Biol Chem 276 (2001) 22086-22089
32. Bode J.G., Ludwig S., Ehrhardt C., Albrecht U., Erhardt A., Schaper F., et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 17 (2003) 488-490
33. Hugli T.E. Structure and functions of anaphylotoxins. Springer Semin Immunopathol 7 (1984) 193-219
34. Vogt W. Drugs and the complement system. Trends Pharmacol Sci 6 (1985) 114-119
35. Ross G.D., and Medof M.E. Membrane complement receptors specific for bound fragments of C3. Adv Immunol 37 (1985) 217-267
36. Worth R.G., Mayo-Bond L., van de Winkel J.G., Todd III R.F., and Petty H.R. CR3 (alphaM beta2; CD11b/CD18) restores IgG-dependent phagocytosis in transfectants expressing a phagocytosis-defective Fc gammaRIIA (CD32) tail-minus mutant. J Immunol 157 (1996) 5660-5665